HSP90B2P and neoplasm: In the 1990s–2000s, clinical trials of HSP-based vaccinations immunomodulation were carried out, including autologous tumor-derived HSP peptide complexes (HSPPCs) [34,87,88], autologous tumor-derived Gp96 peptide complexes (HSPPC-96, Vitespen®, Oncophage), and recombinant oncolytic adenovirus overexpressing HSP70 (H103) [81] (Table 3).